학술논문
Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study.
Document Type
Article
Author
Munir, Talha; Moreno, Carol; Owen, Carolyn; Follows, George; Benjamini, Ohad; Janssens, Ann; Levin, Mark-David; Osterborg, Anders; Robak, Tadeusz; Simkovic, Martin; Stevens, Don; Voloshin, Sergey; Vorobyev, Vladimir; Yagci, Munci; Ysebaert, Loic; Qi, Keqin; Qi, Qianya; Parisi, Lori; Srinivasan, Srimathi; Schuier, Natasha
Source
Journal of Clinical Oncology; 7/20/2023, Vol. 41 Issue 21, p3689-3699, 11p
Subject
Language
ISSN
0732183X